Grant ID DP220043
Awarded On August 17, 2022
Title Oral Amifostine as an upper GI Tract Radioprotectant for Effective Radiotherapy Treatment of Pancreatic Cancer
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization Xerient Pharma Inc.
Principal Investigator/Program Director Cullen Taniguchi
Cancer Sites Pancreas
Contracted Amount $2,934,737*

*Pending contract negotiation

Lay Summary

Pancreatic cancer is almost always fatal and is the third leading cause of cancer-related death in the United States. Pancreatic cancer is difficult to treat because it often cannot be removed by surgery and shrinking the tumors by conventional radiation is significantly limited because the pancreas is next to the intestines (specifically duodenum), which can be easily damaged during radiation treatment. Xerient is a startup dedicated to the development of an orally administered tablet that releases very efficient radioprotectant molecule in the duodenum. Xerient demonstrated that it is possible to repurpose an FDA-approved radioprotectant, and reformulate it in a tablet with a targeted-del...

Read More